Veraxa Biotech is trading at $1.07, up 7.00%, in pre-market, with no specific reason confirmed. - No clear company-specific catalyst dated October 20, 2026, was identified; no volume was confirmed. - The latest company releases found were dated October 13 and October 7. The resurfaced FDA-aligned testing headline refers to the October 7 announcement, not new news. - The biotech sector was reported down pre-market, so it does not explain the gain.